GlassScriptPhysician profile
Morgan Liborio Davis
NPI 1871951145
$3,895.29
in general payments reported to CMS, 2019-2025
28 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $801 · 2022: $954 · 2023: $939 · 2024: $901 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,140.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,049.04 | 2021-2025 | Xtandi |
| Medtronic, INC. | $688.98 | 2023-2024 | Interstim |
| Pfizer INC. | $420.11 | 2021-2025 | |
| Janssen Biotech, INC. | $302.71 | 2022-2023 | Erleada |
| Urogen Pharma, INC. | $281.37 | 2021-2023 | Jelmyto |
| Endo Pharmaceuticals INC. | $198.52 | 2021-2024 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $170.39 | 2023-2024 | Gemtesa |
| Boston Scientific Corporation | $103.96 | 2021 | |
| Coloplast Corp | $84.48 | 2025 | |
| Merck Sharp & Dohme LLC | $74.63 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| 180 Medical, INC. | $65.42 | 2021-2024 | Speedicath |
| Urovant Sciences INC | $64.69 | 2022 | |
| Laborie Medical Technologies Corp. | $48.44 | 2022 | |
| Endo USA, INC. | $40.32 | 2024 | Xiaflex, Aveed |
| Indivior INC. | $37.65 | 2025 | Sublocade |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $37.03 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.62 | 2024 | Givlaari |
| Tolmar, INC. | $24.19 | 2023 | |
| Progenics Pharmaceuticals, INC. | $23.29 | 2025 | |
| Exelixis INC. | $22.78 | 2024 | Cabometyx |
| Axonics, INC. | $20.05 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.49 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.28 | 2023 | Jardiance |
| Antares Pharma, INC. | $17.22 | 2022 | |
| Cardinal Health 414 LLC | $16.63 | 2024 | |
| Procept Biorobotics Corporation | $15.69 | 2022 | |
| Accord Healthcare, INC. | $14.91 | 2024 | |
| Corium, LLC | $11.40 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.